Christina Roaldsnes1, René Holst1,2, Henrik Frederiksen3, Waleed Ghanima1,4. 1. Dept of Medicine, Ostfold Hospital, Norway. 2. Oslo Centre for Biostatistic and Epidemiology, University of Oslo, Oslo University Hospital, Norway. 3. Odense University Hospital, Odense, Denmark. 4. Institute of Clinical Medicine, University of Oslo, Norway.
Abstract
BACKGROUND: Polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) are clonal disorders collectively named as myeloproliferative neoplasms (MPN). Published data on epidemiology of MPN after the discovery of the JAK2 mutation and the 2008 WHO classifications are scarce. We aimed to study the incidence rates, prevalence and survival of MPN in Norway during the period 1993-2012. METHOD: We identified 2453 persons diagnosed with MPN from the Cancer Registry of Norway between 1993 and 2012. We report age-adjusted incidence rates, prevalence, relative survival and standardised mortality rates. RESULTS: The overall age-adjusted yearly incidence rate of PV increased from 0.4/10⁵ to 0.7/10⁵, ET increased from 0.3/10⁵ to 1.0/10⁵ and MF from 0.2/10⁵ to 0.5/10⁵. Prevalence of PV, ET and MF was 9.2, 8.6 and 3.0 per 10⁵ inhabitants, respectively. The five-year relative survival (RS) of ET and PV was slightly reduced with no improvement. The five-year RS of MF was 58.1% (2008-2012). Standardised mortality rate (SMR) was 1.9 (95% CI 1.2 - 2.7). CONCLUSIONS: The incidence rates of ET, PV and MF doubled and tripled during the years 2007-2012 as compared to 1995-2006. This increment in incidence rates may be related to identification of the JAK2 mutation and the derived 2008 WHO guidelines for MPN. The RS was only slightly reduced in PV and ET, but was substantially reduced in MF.
BACKGROUND:Polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) are clonal disorders collectively named as myeloproliferative neoplasms (MPN). Published data on epidemiology of MPN after the discovery of the JAK2 mutation and the 2008 WHO classifications are scarce. We aimed to study the incidence rates, prevalence and survival of MPN in Norway during the period 1993-2012. METHOD: We identified 2453 persons diagnosed with MPN from the Cancer Registry of Norway between 1993 and 2012. We report age-adjusted incidence rates, prevalence, relative survival and standardised mortality rates. RESULTS: The overall age-adjusted yearly incidence rate of PV increased from 0.4/10⁵ to 0.7/10⁵, ET increased from 0.3/10⁵ to 1.0/10⁵ and MF from 0.2/10⁵ to 0.5/10⁵. Prevalence of PV, ET and MF was 9.2, 8.6 and 3.0 per 10⁵ inhabitants, respectively. The five-year relative survival (RS) of ET and PV was slightly reduced with no improvement. The five-year RS of MF was 58.1% (2008-2012). Standardised mortality rate (SMR) was 1.9 (95% CI 1.2 - 2.7). CONCLUSIONS: The incidence rates of ET, PV and MF doubled and tripled during the years 2007-2012 as compared to 1995-2006. This increment in incidence rates may be related to identification of the JAK2 mutation and the derived 2008 WHO guidelines for MPN. The RS was only slightly reduced in PV and ET, but was substantially reduced in MF.
Authors: Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang Journal: Blood Adv Date: 2019-11-26
Authors: M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson Journal: J Intern Med Date: 2020-01-11 Impact factor: 8.989
Authors: Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska Journal: Curr Oncol Date: 2021-04-18 Impact factor: 3.677
Authors: Mohamed A Yassin; Ali Taher; Vikram Mathews; Hsin-An Hou; Tahir Shamsi; Tülin Firatli Tuğlular; Zhijian Xiao; Soo-Jeong Kim; Wu Depei; Junmin Li; Gerd Rippin; Islam Sadek; Asif Siddiqui; Raymond S Wong Journal: Cancer Med Date: 2020-04-30 Impact factor: 4.452
Authors: Erik L Bao; Satish K Nandakumar; Xiaotian Liao; Alexander G Bick; Juha Karjalainen; Marcin Tabaka; Olga I Gan; Aki S Havulinna; Tuomo T J Kiiskinen; Caleb A Lareau; Aitzkoa L de Lapuente Portilla; Bo Li; Connor Emdin; Veryan Codd; Christopher P Nelson; Christopher J Walker; Claire Churchhouse; Albert de la Chapelle; Daryl E Klein; Björn Nilsson; Peter W F Wilson; Kelly Cho; Saiju Pyarajan; J Michael Gaziano; Nilesh J Samani; Aviv Regev; Aarno Palotie; Benjamin M Neale; John E Dick; Pradeep Natarajan; Christopher J O'Donnell; Mark J Daly; Michael Milyavsky; Sekar Kathiresan; Vijay G Sankaran Journal: Nature Date: 2020-10-14 Impact factor: 69.504